- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06781983
Säkerhet och tolerabilitet för IPH4502 hos patienter med avancerade solida tumörer
En fas 1, öppen etikett, multicenterstudie av säkerhet, tolerabilitet och effektivitet hos IPH4502 som ett enda medel i avancerade solida tumörer
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a first-in-human, open-label, multicenter, single-arm Phase 1 study, with a part 1 dose escalation guided by a Bayesian optimal interval design with backfilling (BOIN-BF), followed by a part 2 dose optimization in up to 2 selected indications. This study is to measure the safety, tolerability, pharmacokinetics, and preliminary efficacy of escalating doses of IPH4502 in patients with advanced solid tumors that are known to express Nectin-4.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
-
Lyon, Frankrike, 69008
- Centre Léon Bérard
-
Villejuif, Frankrike, 94805
- Gustave Roussy Cancer Institute
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital - Boston
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- John Theurer Cancer Center
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Mount Sinai Tisch Cancer Center
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75039
- NEXT Oncology - Dallas
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- NEXT Oncology - Virginia
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Main Inclusion Criteria:
- Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4
- Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available.
- Measurable disease according to RECIST 1.1.
- Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor biopsy at baseline.
- Adequate organ function and hematological function.
Main Exclusion Criteria:
- Known or suspected brain metastases.
- Participants with an active infection, Any other infection requiring systemic treatment or latent infection.
- Participants with clinically significant comorbidity(s).
- History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline.
- Condition being treated with systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment.
- Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the first dose of IPH4502.
- Clinically significant cardiovascular disease and/or cardiac repolarization abnormality.
- Participants with symptomatic heart failure, Acute coronary syndromes
- Participant is receiving or has received anticancer therapy prior to enrolment that may have impact on the assessment of IPH4502.
- Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6 months for coronary artery bypass surgery.
- Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior to first dose of IPH4502; systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of IPH4502; systemic use of moderate or strong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: IPH4502 Monoterapi
|
Part 1 (dose escalation) and Part 2 (dose optimization) |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Safety and Tolerability
Tidsram: From time of first dose through treatment period, including the follow-up: up to 24 months
|
To evaluate the incidence of AEs, SAEs, TEAEs, and DLTs. |
From time of first dose through treatment period, including the follow-up: up to 24 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax)
Tidsram: From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To characterize and evaluate the pharmacokinetic profile of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Area Under the Plasma Concentration (AUC)
Tidsram: From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To characterize and evaluate the pharmacokinetic profile of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Incidence of antidrug antibodies (ADA) against IPH4502
Tidsram: From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To evaluate the immunogenicity of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Objective Response Rate (ORR)
Tidsram: From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To investigate any preliminary antitumor activity of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Duration Of Response (DoR)
Tidsram: From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To investigate any preliminary antitumor activity of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
|
Progression Free Survival (PFS)
Tidsram: From time of informed consent through treatment period, including the follow-up: up to 24 months
|
To investigate any preliminary antitumor activity of IPH4502. |
From time of informed consent through treatment period, including the follow-up: up to 24 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- Icke-småcellig lungcancer
- Prostatacancer
- Melanom
- Esofagus skivepitelcancer
- Livmoderhalscancer
- Uroteliala karcinom
- ADC
- Trippelnegativ bröstcancer
- Exatecan
- Kolorektal karcinom
- Skivepitelcancer i huvud och nacke
- Ovariekarcinom
- Antikropp-läkemedelskonjugat
- Topo-Isomeras I-hämmare
- Gastro-esofageal junction och magcancer
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Genitala neoplasmer, manliga
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Genitala sjukdomar, manliga
- Prostatasjukdomar
- Manliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Tarmsjukdomar
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Magsjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Livmodersjukdomar
- Genitala sjukdomar, kvinnor
- Lungsjukdomar
- Neoplasmer i endokrina körtel
- Neoplasmer i huvud och hals
- Neoplasmer, körtel och epitel
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Kolonsjukdomar
- Esofagussjukdomar
- Lungneoplasmer
- Ovariella sjukdomar
- Adnexala sjukdomar
- Genitala neoplasmer, hona
- Gonadal sjukdomar
- Hudsjukdomar
- Bröstsjukdomar
- Carcinom
- Neoplasmer, skivepitelceller
- Livmoderhalssjukdomar
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Uterina neoplasmer
- Neuroendokrina tumörer
- Nevi och melanom
- Neoplasmer i huden
- Karcinom, skivepitel
- Esofagusneoplasmer
- Bröstneoplasmer
- Hud- och bindvävssjukdomar
- Skivepitelcancer i huvud och hals
- Esofagus skivepitelcancer
- Prostatiska neoplasmer
- Neoplasmer i magen
- Kolorektala neoplasmer
- Ovariella neoplasmer
- Karcinom, icke-småcellig lunga
- Uterina cervikala neoplasmer
- Melanom
- Trippelnegativa bröstneoplasmer
- Karcinom, övergångscell
Andra studie-ID-nummer
- IPH4502-101
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .